{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:14:40Z","timestamp":1794834880029,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000291","name":"KIDNEY RESEARCH UK","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Iron deficiency (ID) is common in patients with chronic kidney disease (CKD). Intravenous (IV) iron in heart failure leads to improvement in exercise capacity and improvement in quality-of-life measurements; however, data in patients with CKD are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Iron and the Heart Study was a prospective double blinded randomised study in non-anaemic CKD stages 3b-5 patients with ID which investigated whether 1000\u2009mg of IV iron (ferric derisomaltose (FDI)) could improve exercise capacity in comparison to placebo measured at 1 and 3\u2009months post infusion. Secondary objectives included effects on haematinic profiles and haemoglobin, safety analysis and quality of life questionnaires (QoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We randomly assigned 54 patients mean (SD) age for FDI (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926) 61.6 (10.1) years vs placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928; 57.8 (12.9) years) and mean eGFR (33.2 (9.3) vs. 29.1 (9.6) ml\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      ) at baseline, respectively. Adjusting for baseline measurements, six-minute walk test (6MWT) showed no statistically significant difference between arms at 1\u2009month (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.736), or 3\u2009months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.741). There were non-significant increases in 6MWT from baseline to 1 and 3\u2009months in the FDI arm. Haemoglobin (Hb) at 1 and 3\u2009months remained stable. There were statistically significant increases in ferritin (SF) and transferrin saturation (TSAT) at 1 and 3\u2009months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). There was a modest numerical improvement in QoL parameters. There were no adverse events attributable to IV iron.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated a short-term beneficial effect of FDI on exercise capacity, but it was not significant despite improvements in parameters of iron status, maintenance of Hb concentration, and numerical increases in functional capacity and quality of life scores. A larger study will be required to confirm if intravenous iron is beneficial in iron deficient non-anaemic non-dialysis CKD patients without heart failure to improve the 6MWT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      European Clinical Trials Database (EudraCT) No:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2014-004133-16\">2014-004133-16<\/jats:ext-link>\n                    <\/jats:p>\n                    <jats:p>REC no: 14\/YH\/1209<\/jats:p>\n                    <jats:p>Date First Registered: 2015-02-17 and date of end of trail 2015-05-23<\/jats:p>\n                    <jats:p>Sponsor ref R1766 and Protocol No: IHI 141<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-021-02308-y","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T11:03:34Z","timestamp":1617102214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-9622","authenticated-orcid":false,"given":"S.","family":"Bhandari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Allgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lamplugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Macdougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"issue":"13","key":"2308_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296\u2013305. https:\/\/doi.org\/10.1056\/NEJMoa041031.","journal-title":"N Engl J Med"},{"issue":"4","key":"2308_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/ki.1984.70","volume":"25","author":"SG Rostand","year":"1984","unstructured":"Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int. 1984;25(4):653\u20139. https:\/\/doi.org\/10.1038\/ki.1984.70.","journal-title":"Kidney Int"},{"issue":"3","key":"2308_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.amjcard.2006.01.107","volume":"98","author":"R de Silva","year":"2006","unstructured":"de Silva R, Rigby AS, Witte KK, Nikitin NP, Tin L, Goode K, Bhandari S, Clark AL, Cleland JG. Anaemia, renal dysfunction and their interaction in patients with chronic heart failure. Am J Cardiol. 2006;98(3):391\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2006.01.107.","journal-title":"Am J Cardiol"},{"issue":"2","key":"2308_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","volume":"51","author":"DO Okonko","year":"2008","unstructured":"Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anaemic and nonanaemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomised, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51(2):103\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"2308_CR5","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, L\u00fcscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart RB, Pocock SJ, Poole-Wilson PA, Ponikowski P. FAIR-HF trial investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436\u201348. https:\/\/doi.org\/10.1056\/NEJMoa0908355.","journal-title":"N Engl J Med"},{"issue":"11","key":"2308_CR6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, von Veldhuisen DJ, Comin-Calet J, et al. Beneficial effects of long term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency (CONFIRM-HF). Eur Heart J. 2015;36(11):657\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehu385.","journal-title":"Eur Heart J"},{"key":"2308_CR7","first-page":"295","volume-title":"in Williams hematology","author":"V Fairbanks","year":"2001","unstructured":"Fairbanks V, Beutler E. In: Beutler E, editor. in Williams hematology. 6th ed. New York: McGraw-Hill; 2001. p. 295\u2013304, 447\u2013440.","edition":"6"},{"issue":"2","key":"2308_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.tcb.2006.12.003","volume":"17","author":"LL Dunn","year":"2007","unstructured":"Dunn LL, Rahmanto YS, Richardson DR. Iron uptake and metabolism in the new millennium. Trends Cell Biol. 2007;17(2):93\u2013100. https:\/\/doi.org\/10.1016\/j.tcb.2006.12.003.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"2308_CR9","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2741\/3794","volume":"16","author":"S Bhandari","year":"2011","unstructured":"Bhandari S. Risk factors and pathophysiology of metabolic change in uraemic cardiac disease. Front Biosci (Landmark Ed). 2011;16(1):1364\u201387. https:\/\/doi.org\/10.2741\/3794.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"(1)22","key":"2308_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1681\/ASN.2009090900","volume":"8","author":"D Semple","year":"2011","unstructured":"Semple D, Smith K, Bhandari S, Seymour AM. Uraemic cardiomyopathy and insulin resistance: a critical role for Akt. J Am Soc Nephrol. 2011;8((1)22):207\u201315.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2308_CR11","doi-asserted-by":"publisher","first-page":"F579","DOI":"10.1152\/ajprenal.00442.2014","volume":"308","author":"D Taylor","year":"2015","unstructured":"Taylor D, Bhandari S, Seymour AM. Mitochondrial dysfunction in uraemic cardiomyopathy. Am J Physiol Ren Physiol. 2015;308(6):F579\u201387. https:\/\/doi.org\/10.1152\/ajprenal.00442.2014.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"21","key":"2308_CR12","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1161\/CIRCULATIONAHA.118.038516","volume":"139","author":"G Charles-Edwards","year":"2019","unstructured":"Charles-Edwards G, Amaral N, Sleight A, Ayis S, Catibog N, McDonagh T, et al. Effects of Iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency (FERRIC-HF II). Circulation. 2019;139(21):2386\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038516.","journal-title":"Circulation."},{"key":"2308_CR13","doi-asserted-by":"crossref","unstructured":"Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJ, Murray H, Steenkamp R, Tomson CRV, Wheeler CD, Winearls CG, Ford I on behalf of the PIVOTAL Study investigators 2018. Randomised controlled trial comparing high-dose versus low-dose intravenous iron supplementation in haemodialysis (PIVOTAL): study design and baseline data. Am J Nephrol. 48:260\u20138.","DOI":"10.1159\/000493551"},{"key":"2308_CR14","unstructured":"Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJ, Murray H, Steenkamp R, Tomson CRV, Wheeler CD, Winearls CG, Ford I on behalf of the PIVOTAL Study investigators 2019. Randomised controlled trial comparing high-dose versus low-dose intravenous iron supplementation in hemodialysis (PIVOTAL). New Eng J Med. 380:447\u201358."},{"issue":"11","key":"2308_CR15","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"C Iain","year":"2014","unstructured":"Iain C, Macdougall IC, Aarau K, Block AH, Carrera F, Eckardt K-U, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD, on behalf of the FIND-CKD Study Investigators. FIND-CKD: a randomised trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29(11):2075\u201384 https:\/\/doi.org\/10.1093\/ndt\/gfu201.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2308_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/ndt\/gfv293t","volume":"31","author":"PA Kalra","year":"2016","unstructured":"Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW. A randomised trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31(4):646\u201355. https:\/\/doi.org\/10.1093\/ndt\/gfv293t.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2308_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1159\/000507872","volume":"51","author":"S Bhandari","year":"2020","unstructured":"Bhandari S, Allgar V, Lamplugh A, Macdougall KPI. Protocol and baseline data of a multicentre prospective double blinded randomised study of intravenous iron on functional status in patients with chronic kidney disease. Am J Nephrol. 2020;51(6):493\u2013500. https:\/\/doi.org\/10.1159\/000507872.","journal-title":"Am J Nephrol"},{"issue":"5","key":"2308_CR18","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3747\/pdi.2018.00272","volume":"39","author":"H Dukka","year":"2019","unstructured":"Dukka H, Kalra PA, Wilkie M, Bhandari S, Davies SJ, Barrat J, Odudu A, Selby NM, McIntyre C, Robertson F, Taal MW. Peritoneal ultrafiltration for heart failure; lessons learned from a randomised controlled trial. Perit Dial Int. 2019;39(5):486\u20139. https:\/\/doi.org\/10.3747\/pdi.2018.00272.","journal-title":"Perit Dial Int"},{"issue":"1","key":"2308_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","volume":"89","author":"IC Macdougall","year":"2016","unstructured":"Macdougall IC, Bircher IC, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, Swinkels DW, Wanner C, Weiss G, Chertow GM, for Conference Participants. Iron management in chronic kidney disease: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference. Kidney Int. 2016;89(1):28\u201339. https:\/\/doi.org\/10.1016\/j.kint.2015.10.002.","journal-title":"Kidney Int"},{"issue":"1","key":"2308_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","volume":"18","author":"A Mikhail","year":"2017","unstructured":"Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Isaac H, Bhandari S. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol. 2017;18(1):345.","journal-title":"BMC Nephrol"},{"key":"2308_CR21","series-title":"Clinical guidelines NG8","volume-title":"Chronic kidney disease: managing anaemia","author":"National Institute for Health and Clinical Excellence","year":"2015","unstructured":"National Institute for Health and Clinical Excellence. Chronic kidney disease: managing anaemia. Clinical guidelines NG8. 2015. https:\/\/www.nice.org.uk\/guidance\/ng8."},{"issue":"(4)103","key":"2308_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph11040103","volume":"11","author":"F Nuhu","year":"2018","unstructured":"Nuhu F, Bhandari S. Oxidative stress and cardiovascular complications in CKD, the impact of anaemia. Iron Ther Targets Hum Diseases Pharm. 2018;11((4)103):1\u201315. https:\/\/doi.org\/10.3390\/ph11040103.","journal-title":"Iron Ther Targets Hum Diseases Pharm"},{"issue":"4","key":"2308_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/ph11040104","volume":"111","author":"S Bhandari","year":"2018","unstructured":"Bhandari S, Pereira DIA, Chappell HF, Drakesmith H. Intravenous irons: from basic science to clinical practice. Pharmaceuticals. 2018;111(4):103. https:\/\/doi.org\/10.3390\/ph11040104.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"2308_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1681\/ASN.2005080876","volume":"18","author":"V Reddy","year":"2007","unstructured":"Reddy V, Bhandari S, Seymour AM. Myocardial function, energy provision and carnitine deficiency in experimental uraemia. J Am Soc Nephrol. 2007;18(1):84\u201392. https:\/\/doi.org\/10.1681\/ASN.2005080876.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2308_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/ki.2008.691","volume":"75","author":"D Aksentijevi\u0107","year":"2009","unstructured":"Aksentijevi\u0107 D, Bhandari S, Seymour AM. Insulin resistance and altered glucose transporter 4 expression in experimental uraemia. Kidney Int. 2009;75(7):711\u20138. https:\/\/doi.org\/10.1038\/ki.2008.691.","journal-title":"Kidney Int"},{"key":"2308_CR26","first-page":"1942","volume":"2","author":"K Smith","year":"2010","unstructured":"Smith K, Semple D, Aksentijevi\u0107 D, Bhandari S, Seymour AM. Functional and metabolic adaptation in uraemic cardiomyopathy. Front Biosci (Elite Ed). 2010;2:1942\u2013501.","journal-title":"Front Biosci (Elite Ed)"},{"issue":"17","key":"2308_CR27","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","volume":"50","author":"JE Toblli","year":"2007","unstructured":"Toblli JE, Lombra\u00f1a A, Duarte P, Di Genarro F. Intravenous iron reduces NT pro brain natriuretic peptide in anaemia patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50(17):1657\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2007.07.029.","journal-title":"J Am Coll Cardiol"},{"issue":"Supplement 1","key":"2308_CR28","doi-asserted-by":"publisher","first-page":"i315","DOI":"10.1093\/ndt\/gfy104","volume":"33","author":"PA Kalra","year":"2018","unstructured":"Kalra PA, Bhandari S, Spyridon M, Davinson R, McCafferty K, Mikhail A, Reaich D, Lawman S, Moore J. The NIMO UK study: is 1000 mg of intravenous iron enough to achieve Hb targets in pre-dialysis anaemia patients? Nephrol Dial Transplant. 2018;33(Supplement 1):i315\u20136. https:\/\/doi.org\/10.1093\/ndt\/gfy104 NDT Abstract Supplement 2018.","journal-title":"Nephrol Dial Transplant"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02308-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-021-02308-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02308-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T11:04:57Z","timestamp":1617102297000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02308-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2308"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02308-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-59541\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"17 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was given a favourable opinion from the Northern Regional Ethics Service (NRES) Committee Yorkshire & The Humber - Leeds East, UK), approval reference number 10\/H1306\/40. Study participants had all details explained to them in writing and in person before giving informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Neither this manuscript nor substantial parts of it are under consideration for publication elsewhere, have been published nor made available elsewhere in a manner that could be construed as a prior or duplicate publication of the same content. Otherwise not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VA declare no conflicts of interest. SB, IM and PK have received honorarium for lectures, attended expert opinion committees and received educational funds to attend International Nephrology meetings from Pharmacosmos A\/S and Vifor Pharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}